Identification of Mycobacterium tuberculosis CtpF as a target for designing new antituberculous compounds
MetadataShow full item record
Mata Espinosa D.
The emergence of tuberculosis (TB) produced by multi-drug resistance (MDR) and extensively-drug resistance (XDR) Mycobacterium tuberculosis (Mtb), encourages the development of new antituberculous compounds, as well as the identification of novel drug targets. In this regard, plasma membrane P-type ATPases are interesting targets because they play a crucial role in ion homeostasis and mycobacterial survival. We focused on Mtb CtpF, a calcium P-type ATPase that responds to a broad number of intraphagosomal conditions, as a novel target. In this study, we evaluated the capacity of cyclopiazonic acid (CPA), a well-known inhibitor of the sarco-endoplasmic reticulum Ca2+-ATPase (SERCA), to inhibit the ATPase activity of CtpF and the Mtb growth demonstrating that CtpF is a druggable target. A homology modeling of CtpF was generated for molecular docking studies of CtpF with CPA and key pharmacophoric features were identified, which were used to perform a pharmacophore-based virtual screening of the ZINC database, and to identify CtpF inhibitor candidates. Molecular docking-based virtual screening and MM-BGSA calculations of candidates allowed identifying six compounds with the best binding energies. The compounds displayed in vitro minimum inhibitory concentrations (MIC) ranging from 50 to 100 μg/mL, growth inhibitions from 29.5 to 64.0% on Mtb, and inhibitions of Ca2+-dependent ATPase activity in Mtb membrane vesicles (IC50) ranging from 4.1 to 35.8 μM. The compound ZINC63908257 was the best candidate by displaying a MIC of 50 μg/mL and a Ca2+ P-type ATPase inhibition of 45% with IC50 = 4.4 μM. Overall, the results indicate that CtpF is a druggable target for designing new antituberculous compounds. © 2019 Elsevier Ltd
Showing items related by title, author, creator and subject.
Inhibition of C. albicans dimorphic switch by cobalt(II) complexes with ligands derived from pyrazoles and dinitrobenzoate: Synthesis, characterization and biological activity (2020) Fonseca D.; Leal-Pinto S.M.; Roa-Cordero M.V.; Vargas J.D.; Moreno-Moreno E.M.; Macías M.A.; Suescun L.; Muñoz-Castro Á.; Hurtado J.J. (MDPI AG, 2019)
ReviewChávez F.P.; Lagos C.F.; Reyes-Parada M.; Guiliani N.; Jerez C.A. (2011)
ArticleRamírez D.; Concha G.; Arévalo B.; Prent-Peñaloza L.; Zúñiga L.; Kiper A.K.; Rinné S.; Reyes-Parada M.; Decher N.; González W.; ... (MDPI AG, 2019)